GVHD - GRAFT-VERSUS-HOST DISEASE
Clinical trials for GVHD - GRAFT-VERSUS-HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new GVHD - GRAFT-VERSUS-HOST DISEASE trials appear
Sign up with your email to follow new studies for GVHD - GRAFT-VERSUS-HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Ancient herb, modern hope: ashwagandha compound tested to prevent deadly transplant complication
Disease control Recruiting nowThis trial tests whether a compound from the herb ashwagandha, called withaferin A, can help prevent graft-versus-host disease (GvHD) in people receiving a stem cell transplant for blood cancer. GvHD is a serious complication where donated immune cells attack the recipient's body…
Matched conditions: GVHD - GRAFT-VERSUS-HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Ancient herb takes on transplant complication: Withaferin-A tested for Steroid-Resistant GVHD
Disease control Recruiting nowThis phase 2 trial tests whether a standardized extract from the ashwagandha plant, called Withaferin-A, can help people who develop graft-versus-host disease after a stem cell transplant and whose condition does not improve with steroids. The study enrolls 34 patients aged 12 an…
Matched conditions: GVHD - GRAFT-VERSUS-HOST DISEASE
Phase: PHASE2 • Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Depression may worsen GvHD symptoms, new study investigates
Knowledge-focused Recruiting nowThis study looks at how depression and other mental health issues impact symptom severity and quality of life in people with graft-versus-host disease (GvHD). Researchers will follow 200 adults with GvHD, using questionnaires to measure psychiatric status and symptoms. The goal i…
Matched conditions: GVHD - GRAFT-VERSUS-HOST DISEASE
Sponsor: Medical University of Gdansk • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC